Atara Biotherapeutics (ATRA) to Release Quarterly Earnings on Thursday

Atara Biotherapeutics (NASDAQ:ATRA) is expected to be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Atara Biotherapeutics to post earnings of ($3.82) per share and revenue of $16.65 million for the quarter.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Friday, March 7th. The biotechnology company reported ($1.19) EPS for the quarter, topping the consensus estimate of ($3.82) by $2.63. The business had revenue of $32.75 million for the quarter, compared to analyst estimates of $20.58 million. On average, analysts expect Atara Biotherapeutics to post $-10 EPS for the current fiscal year and $-10 EPS for the next fiscal year.

Atara Biotherapeutics Stock Performance

Shares of Atara Biotherapeutics stock opened at $6.92 on Wednesday. The firm has a fifty day moving average of $7.74 and a two-hundred day moving average of $9.67. The stock has a market capitalization of $40.54 million, a price-to-earnings ratio of -0.27 and a beta of 0.49. Atara Biotherapeutics has a 52 week low of $5.40 and a 52 week high of $20.81.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $17.00 price target on shares of Atara Biotherapeutics in a research report on Tuesday, March 11th. RODMAN&RENSHAW downgraded Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 21st. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a report on Tuesday, January 28th. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Finally, Rodman & Renshaw assumed coverage on Atara Biotherapeutics in a research note on Friday, December 20th. They issued a “buy” rating and a $25.00 price target on the stock. One research analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.75.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.